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Abstract The aim of this study was to investigate the
anthropometric, metabolic, cardiovascular and symptomatic
profile in gynoid and android postmenopausal women.
Forty five postmenopausal women aged 50 to 60 years
were divided into two groups according to fat distribution
[waist-to-hip ratio (WHR)]: gynoid group (WHR between
0.68 and 0.8; N=13) and android group (WHR>0.8; N=
32). Body composition, skinfold thickness, serum/plasma
estradiol, creatinine, urea, lipid profile, glucose and insulin,
maximal exercise testing and menopause rating scale
(MRS) were evaluated. The android group when compared
to the gynoid group showed (P<0.05): (i) higher values of
body mass, BMI, waist circumference, body fat, lean mass
and skinfold thickness; (ii) higher values of estradiol,
triglycerides, very low-density lipoprotein (VLDL) and
insulin levels with lower insulin sensitivity (%S) and great-
er insulin resistance (%IR) index; (iii) higher blood pres-
sure (BP) during rest and lower maximal heart rate
(HRmax) during maximal exercise testing and; (iv) higher
scores of the somatic and urogenital-sexual symptoms. This
study suggests that android postmenopausal women develop
features that can lead to metabolic syndrome (MetS) and
future cardiovascular disease (CVD), and these women
may present higher scores of somatic and urogenital-sexual
symptoms.
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Introduction
Changes in body composition have been observed in post-
menopausal women, due to hormonal changes [1]. After the
menopause, the gynoid fat distribution gradually changes to
an android distribution with an increased upper body fat, in
the abdominal region [2]. These are associatedwith decreased
aerobic capacity and reduced total energy expenditure [3] and
may lead to the metabolic syndrome (MetS), as evidenced by
androgenic obesity, insulin resistance, diabetes melittus (type
II), hypertension and dyslipidemia [4, 5]. According to the
National Cholesterol Education Program/Adult Treatment
Panel III (NCEP/ATP III) definition [6], MetS is diagnosed
when three of the above mentioned criteria are met, and CVD
is the leading cause of mortality and morbidity in postmeno-
pausal woman [2].
It is not clear whether the transition to menopause in-
creases the CVD risk for all women or only for those who
develop features of the MetS [7]. Studies [8, 9] have iden-
tified the menopausal transition a trigger for changes in the
body fat distribution in healthy middle-aged women.
Moreover, the type of body fat distribution is related to the
possibility of developing metabolic disorder, mainly as an-
drogenic obesity plays an important role in MetS [5, 10].
The objective of our study was to investigate anthropo-
metric, metabolic, cardiovascular and symptomatic profiles
in gynoid and android postmenopausal women. The hypoth-
esis of the present study was that postmenopausal andro-
genic obesity increases both the risk of developing MetS
and CVD, as well as the magnitude of the postmenopausal
symptoms, when compared to gynecoid obesity.
Materials and methods
The study research has been approved by the Ethics Committee
of the Federal University of São Carlos (UFSCar) in São
Carlos, Brazil (no. 159/2010). All participants signed a written
consent form before starting the first testing session. The study
was registered with NIH Clinical Trials (NCT01745042).
Participants
A cross-sectional survey was conducted. Inclusion criteria
were healthy postmenopausal Caucasian women, Brazilians,
between 50 and 60 years of age. The postmenopausal
period was defined by an absence of menstruation for
more than 12 months. Exclusion criteria were symptoms
and signs of any neurological, metabolic, inflammatory
and/or cardiologic disease as well as cigarette smoking
and use of any mediators, including hormone replace-
ment therapy (HRT). The women were divided according to
the fat distribution [waist-to-hip ratio (WHR)] [11] into two
groups:
1) Gynoid (WHR between 0.68 and 0.8; N=13)
2) Android (WHR>0.8; N=32)
Assessment of body composition and skinfolds
Anthropometric data were used to determine the body mass
index [BMI: body weight (in kg) divided by height (in m)
squared] and the WHR [waist circumference (in cm) divided
by hip circumference (in cm)]. The anatomical landmarks to
measure the circumference (cm), in the upright position of
the body were: 1) waist: measured at the above the iliac
crest; 2) hip: measured at the largest protuberance of the
buttocks [12]. The body fat and lean mass were measured by
the bipolar electrical bioimpedance of the upper limbs
(OMRON®, Kyoto, Japan) [13]. The measurements of the
skinfolds (in mm) were performed in the upright position,
the caliper was placed at specific locations on the right side
of the body, which was relaxed and dry. Three measure-
ments were reformed at each location to obtain an average.
The anatomic locations for these measurements were: tri-
ceps, subscapular, suprailiac, abdominal, anterior thigh, me-
dial calf [14, 15].
Assessment of biochemical exams
Blood was collected after a 12-hour fasting according to
standard laboratory procedures of the Medical School
Hospital of our Institution. Serum level of estradiol, urea,
creatinine, triglycerides, total cholesterol, high-density lipo-
protein (HDL) cholesterol, low-density lipoprotein (LDL)
cholesterol, very low-density lipoprotein (VLDL) cholesterol,
insulin and glucose were measured. Low-density lipoprotein
(LDL) cholesterol was calculated according to Friedewald’s
formula [LDL=colesterol total−(HDL+VLDL)]. Very low-
density lipoprotein (VLDL) cholesterol was calculated according
to: triglycerides divided by 5.
AccordingtotheCastelli Index,higherLDLlevelsand lower
HDL levels result in greater risk [16, 17]: (i) Castelli Index I:
total cholesterol/HDL, (ii) Castelli index II: LDL/HDL.
The Homeostasis Model Assessment (HOMA) β, which
estimates the functioning of pancreatic β cells, the HOMA
%S, which estimates insulin sensitivity and HOMA %IR,
which estimates insulin resistance were calculated [18]. The
reference values for some of the parameters are: glucose≤
100 mg/dL, insulin from 2.6 to 24.9 uUI/ml, triglycerides≤
150 mg/dL, total cholesterol≤200 mg/dl and HDL≥50 mg/dL,
LDL≤130 mg/dL and VLDL up to 40 mg/dL [5, 19, 20].
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Assessment of cardiovascular responses during rest
and maximal exercise testing
The subjects had a 12-lead conventional ECG recording
(Ergo, HeartWare Ltda, Belo Horizonte, MG, Brazil) under
rest and an ergometric test. For the incremental exercise
testing on a treadmill we used the Modified Bruce
Protocol [21]. The systolic blood pressure (SBP) and the
diastolic blood pressure (DBP) were measured at rest and at
each step of the test using the auscultatory sphygmomanom-
eter. Estimated maximum oxygen consumption (VO2max)
achieved at peak exercise [22] was determined using the
method described by the American Heart Association [23].
The metabolic equivalents (METs) were determined by the
formula: VO2 / 3.5 [23].
Assessment of menopause symptoms
Symptoms of menopause were assessed by the Meno-
pause Rating Scale (MRS) of Hauser et al. [24], translated
into Portuguese and was previously used in a descriptive
study [25]. The MRS questionnaire is composed of 11
items divided into three subscales: (1) somatic symptoms
such as hot flashes, heart discomfort, sleeping problems,
and muscle and joint problems (items 1–3 and 11); (2)
psychological symptoms such as depressive mood, irrita-
bility, anxiety, and physical and mental exhaustion (items
4–7); and (3) urogenital-sexual problems such as bladder
problems and vaginal dryness (items 8–10). The total
score per each subscale (somatic, psychological, and
urogenital-sexual) is the sum of each graded item
contained in that subscale. The total MRS score is the
sum of the scores obtained for each subscale. The scores
were also obtained by averaging the items. The magnitude
of the symptoms can be categorized according to the
severity of the symptoms for each domain of the MRS:
absent or occasional (0–4 points), mild (5–8 points), mod-
erate (9–15 points) or severe (≥16 points). Higher scores
obtained by the MRS point toward severe symptoms and
a poor quality of life [25].
Statistical analysis
Measurements were expressed as mean and standard de-
viations. The Shapiro-Wilk test was used to analyze the data
normality. Comparisons between the gynoid and android
groups were made using the unpaired Student’s t test. To
investigate the relationship between the key variables, we
used the Pearson product–moment correlation coefficients.
The level of statistical significance was 5 % (P<0.05). For
the statistical analysis the software Statistica for Windows
Release 7 (Statsoft Inc., Tulsa, OK) was used.
Results
The clinical characteristics can be seen in Table 1. The
android group showed significantly higher values for body
mass, BMI, waist circumference, body fat, lean mass and
skinfolds (P<0.05). Compared to gynoid group, android
women had significantly higher values of estradiol, triglyc-
erides, VLDL, Castelli index I and insulin with lower insu-
lin sensitivity and greater insulin resistance. The SBP and
DBP values during rest were significantly higher, and the
maximal heart rate (HRmax) during maximal exercise test-
ing showed lower values for the android group (P<0.05)
(Table 2). There were no significant differences (P≥0.05) in
the estimated VO2max (Table 2). The magnitude of the
somatic and urogenital-sexual symptoms was significantly
higher for the android group compared to the gynoid group
(Table 3).
There were lower but significant correlations between
estradiol and body fat (r=0.41, P<0.01) as well as WHR
for both triglycerides (r=0.42, P<0.01) and insulin (r=0.34,
P<0.05). There were also significant correlations between
waist circumference with Castelli index I (r=0.43, P<0.01,
Fig. 1a). SBP during rest was moderately correlated to
subscapular skinfold (r=0.56, P<0.001, Fig. 1b), suprailiac
skinfold (r=0.47, P<0.01), triceps skinfold (r=0.32, P<
0.05), abdominal skinfold (r=0.39, P<0.01), body fat (r=
0.51, P<0.001), triglycerides (r=0.32, P<0.05) and glucose
(r=0.51, P<0.001). Regarding the menopause symptoms,
there were lower but significant inverse correlations be-
tween the HOMA %β-cell and the somatic symptoms (r=
−0.39, P<0.05) as well as positive correlations between
urogenital-sexual symptoms and circumference of waist
(r=0.37, P<0.05, Fig. 1c).
Discussion
This study shows that android postmenopausal women de-
velop features that can lead to MetS, and that they have
higher scores of somatic and urogenital-sexual symptoms.
Estradiol levels had positive correlations with body fat. In
abdominal fat stores, androgens are converted to estrogen
[12] which stimulates lipogenesis [26] and can explain that
higher BMI, body fat percentage and subcutaneous fat in the
android group. A mobilization of fat from the adipocytes to
the visceral region is related to changes in the glucose
utilization that leading to insulin resistance, increased lipid
accumulation and increased production of triglycerides.
Hyperinsulinemia results in enhanced sodium reabsorption
and increased sympathetic nervous system activity, which
may contribute to hypertension, and to increased levels of
free fatty acids [27].
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The accumulation of abdominal fat (android pattern),
dyslipidemia and hypertension have a higher incidence in
women after menopause compared to those with irregular
menstrual cycles (perimenopause) and with regular cycles
[4]. Thus, MetS risk factors are increased during the post
menopause. Our study also identified that the android group
showed higher values of triglycerides, VLDL and insulin
with an increase of the HOMA %IR and a reduction of
the HOMA %S compared to the gynoid group. Still,
both triglycerides and insulin had positive correlations
with WHR.
The increase of the insulin can lead to an increased blood
glucose (compensatory mechanism) mainly because there
was greater insulin resistance, which indicates an increased
risk of developing type 2 diabetes mellitus [27]. Moreover,
our data suggest that android postmenopausal women de-
veloped features of the MetS with an increased risk of CVD,
as evidenced by insulin resistance, Castelli index and hy-
pertension [5, 6, 8, 10].
The increased CVD risk among postmenopausal women
may be associated with a progressive decrease in insulin
sensitivity as a consequence of increased visceral adipose
Table 1 Values of mean and
standard deviation and statistical
results of clinical characteristics
of the women
NS No significant difference was
found between the groups, W/H
Waist-to-hip ratio, 6 skinfolds
sum of six skinfolds, HDL high-
density lipoprotein, LDL low-
density lipoprotein, VLDL very
low-density lipoprotein, HOMA
homeostasis model assessment,
S insulin sensitivity, IR insulin
resistance
Gynoid group (N=13) Android group (N=32) P value
Anthropometric characteristics
Age (years) 56±2 55±2 NS
Duration of menopause (years) 8±4 8±6 NS
Body composition and skinfold thickness
Body mass (Kg) 62±10 76±13 <0.05
Height (cm) 155±7 157±6 NS
BMI (Kg/m2) 26±4 31±5 <0.05
Waist (cm) 83±9 101±10 <0.01
Hip (cm) 104±9 109±10 NS
W/H (cm/cm) 0.79±0.03 0.92±0.05 <0.01
Body fat (%) 36±4 41±4 <0.01
Fat mass (Kg) 22±6 31±8 <0.01
Lean mass (Kg) 40±6 45±5 <0.05
Triciptal (mm) 28±7 34±6 <0.01
Subescapular (mm) 26±8 37±6 <0.01
Suprailiac (mm) 23±9 33±7 <0.01
Abdominal (mm) 30±6 38±5 <0.01
Anterior thigh (mm) 38±8 44±6 <0.05
Medial calf (mm) 31±9 35±8 NS
Σ6 skinfolds (mm) 174±44 224±34 <0.01
Biochemical exams
Estradiol (pg/ml) 14±11 20±11 <0.05
Creatinine (mg/dl) 0.8±0.09 0.78±0.12 NS
Urea (mg/dl) 31±9 33±7 NS
Triglycerides (mg/dl) 117±106 177±85 <0.01
Total cholesterol (mg/dl) 225±39 233±49 NS
HDL(mg/dl) 55±12 50±10 NS
LDL (mg/dl) 146±29 147±41 NS
VLDL (mg/dl) 23±19 36±17 <0.01
Castelli index I 4±1.6 4.8±1.4 <0.05
Castelli index II 2.6±1.3 2.9±0.9 NS
Glucose (mg/dl) 93±15 98±21 NS
Insulin (μUl/ml) 4±3 8±5 <0.01
HOMA %β-cell 76±23 94±45 NS
HOMA %S 155±67 76±61 <0.05
HOMA %IR 0.8±0.35 1.6±1.3 <0.05
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tissue mass, emphasizing the importance of considering
body fat distribution [28]. However, this study showed that
HRT protects against the negative effects of increased vis-
ceral adiposity in postmenopausal women [28].
Both chronological age and ovarian age contributed to
substantial changes in body composition, increasing the fat
mass and the waist circumference over a 6 years period for
premenopausal or perimenopausal women. These changes
have important implications by establishing a metabolic
environment which can be considered healthy or un-
healthy [29], mainly for postmenopausal women. The
recent study of Goss et al. [30] showed that the endo-
crine environment (i.e., circulating estrogen, free testos-
terone, cortisol and sex-hormone-binding globulin sta-
tus) is associated with fat distribution in healthy post-
menopausal women. This study suggests that the HRT gen-
erates a higher level of circulating estradiol which limits the
lipid deposition in the intra-abdominal cavity. On the other
hand, high proportion of weak estrogens may promote a gain
of intra-abdominal adipose tissue over time. Moreover, post-
menopausal women not using HRTmay limit intra-abdominal
adipose tissue accrual due to the higher circulating free tes-
tosterone [30]. Another study showed conflicting results,
demonstrating that after menopause, an abdominal yet not
gluteofemoral fat distribution is associated with high levels
of free estradiol and free testosterone and with low levels of
sex hormone-binding globulin [31]. Further studies are there-
fore needed to elucidate the mechanism by which sex hor-
mones profiles regulate a lipid deposition in postmenopausal
women and the extent to which HRT may affects these
relationships.
The sample size limitations in the gynoid group seen in
the our study may be explained by the changes in the body
composition with a gain of upper body fat and abdominal fat
(subcutaneous and visceral) possibly due to hormonal de-
cline observed during the postmenopausal period. This fat
distribution is similar to that reported previously [28–31],
reflecting the contribution of sex hormone profiles to the
accumulation of abdominal fat.
No significant difference between the groups was found
for the estimated VO2max which indicates that women in
both groups showed similar levels of aerobic fitness.
However, the android group showed higher values of SPB
and DPB during rest as well as lower HRmax. The lower
HRmax for the android group may indicate a compen-
satory mechanism of depressed chronotropic responses
[32]. In this context, autonomic nervous control of the
heart rate could be analyzed in the future, as depressed
autonomic responses have been observed in arterial hy-
pertension [33].
Our results showed that the upper body subcutaneous fat
(triceps, subescapular and suprailiac), serum triglycerides and
blood glucose had a positive correlation with SPB. This in-
dicates that women with a higher fat percentage, mainly
android postmenopausal women, can develop hypertension
Table 2 Values of mean and
standard deviation and statistical
results of the cardiovascular pa-
rameters during rest and maxi-
mal exercise testing
NS No significant difference was
found between the groups, HR
Heart rate, SBP systolic blood
pressure, DBP diastolic blood
pressure, VO2max maximal oxy-
gen consumption, METs equiva-
lent metabolic
Gynoid group (N=13) Android group (N=32) P value
Rest
HR (beats/min) 69±7 73±9 NS
SBP (mmHg) 118±15 134±19 <0.01
DBP (mmHg) 76±8 80±10 <0.01
Exercise peak
HR max (beats/min) 163±10 138±35 <0.05
SBP (mmHg) 162±19 164±20 NS
DBP (mmHg) 77±8 79±10 NS
VO2 max (ml/kg/min) 28.1±7.9 27.7±7.1 NS
METs reaching 8.1±4.2 7.9±2.1 NS
Bruce (stage) 2.5±0.7 2.4±0.6 NS
Table 3 Values of mean and standard deviation of menopause symp-
toms by Menopause Rating Scale (MRS)
Gynoid group (N=13) Android group (N=32) P value
Somatic symptoms score
Sum 4.3±2.5 6.4±2.3 <0.05
Mean 1.1±0.6 1.5±0.8 <0.05
Psychological symptoms score
Sum 5.6±0.7 6.3±0.5 NS
Mean 1.4±0.7 1.6±0.9 NS
Urogenital-sexual symptoms score
Sum 2.7±1.8 4.6±1.9 <0.05
Mean 0.9±0.8 1.6±0.9 <0.05
Total score
Sum 14.6±6.9 16.4±5.6 NS
Mean 1.3±0.6 1.5±0.5 NS
A significant difference was found between the groups for the sum and
mean of the somatic and urogenital-sexual symptoms (P<0.05)
NS No significant difference was found between the groups
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Fig. 1 Correlations between
variables in gynoid (N=13)
and android (N=32)
postmenopausal women. Waist
circumference as a function of
Castelli index: the regression
line represents both the average
of the waist circumference and
the Castelli index; the
regression (r=0.43) was
statistically significant at
P=0.01 (a). Subescapular
skinfold as a function of
systolic pressure: the regression
line represents both the average
of the subescapular skinfold
and the systolic blood pressure;
the regression (r=0.56) was
statistically significant at
P=0.000 (b). Waist
circumference as a function of
urogenital-sexual symptoms:
the regression line represents
both the average of the waist
circumference and the
urogenital-sexual symptoms;
the regression (r=0.37) was
statistically significant at
P=0.02 (c)
Int J Diabetes Dev Ctries (January–March 2014) 34(1):32–39 37
associated with dyslipidemia and insulin resistance with at-
tendant complications [19]. These findings were corroborated
by a longitudinal study, where even in adolescents (12–
18 years) the increase in blood pressure was associated with
an increased BMI, abdominal fat and upper body subcutane-
ous fat [15]. Moreover, in another study, Lee et al. [34]
observed that postmenopausal women with MetS showed a
higher total score of MRS and a higher subscale score for the
somatic symptoms.
Higher somatic symptoms were observed in the android
group. Hot flush, sweating, insomnia, dizziness and heart
discomfort, palpitations and, muscle and, joint problems occur
with a higher frequency in postmenopausal women, mainly for
those with an increased body mass. Android fat distribution
and a higher BMI can result in a poor quality of life during
menopause [11].
Weakness and fatigue of the lower abdominal and pelvic
floor muscles in postmenopausal women can result in uri-
nary incontinence. Higher BMI can result in a higher intra-
abdominal pressure and in development and recurrence of
urinary incontinence [35]. Lower levels of sexual desire and
lower frequency of penile–vaginal intercourse were associ-
ated with more body fat and larger waist or hip circumfer-
ence as well as lower arousal, orgasm, and lubrication, when
associated with MetS during the premenopausal state [36,
37]. Moreover, sexual pain and orgasmic disorder also occur
due to hypoestrogenemia [38].
However, in our study, the psychological symptoms were
similar for the both groups, being commonly encountered
by women in this period of life [39] and they were not
influenced by the type of fat distribution. A descriptive
study in Brazil showed that perimenopausal women, but
not postmenopausal women, were at greater risk to undergo
minor psychiatric disorders [40]. A low level of education,
memory loss, irritability, and the menopausal transition were
risk factors which may lead to positive findings in a screen-
ing for minor psychiatric disorders [40]. However, the mag-
nitude of all symptoms estimated by MRS for the gynoid
and android group ranged from occasional to moderate. This
may be due to the fact that, probably, a higher magnitude of
these symptoms occurs in the menopausal transition.
However, an advantage for the android group observed in
the current study is the larger muscle mass compared to the
gynoid group. This is important since the aging process in-
duces a loss of muscle mass due to atrophy and neuromuscular
degeneration [41]. The bigger muscle mass in the obese
postmenopausal women can be influenced by weight-
bearing effects, which improves muscular function [22].
Several strategies have been developed to reduce MetS
and CVD risk factors, for example, medication use [42], diet
programs [43], physical exercise program [44] and
phototherapeutic technologies such as treatments using laser
[45] or light-emitting diodes (LED) [46].
The limitations of this study were: we only used anthro-
pometric parameters and electrical bioimpedance to measure
body composition and these do not distinguish between
accumulations of visceral and subcutaneous abdominal fat.
In this context, imaging techniques (e.g., computed tomog-
raphy, magnetic resonance and ultrasonography), which
can distinguish fat from other tissues should be used in
future studies.
In conclusion, postmenopausal women with central obesity
present a greater risk to developMetS and CVD, because these
women showed higher rates of hypertension, dyslipidemia,
insulin resistance and hyperinsulinemia, leaving them prone
to the development of a higher magnitude of somatic and
urogenital-sexual symptoms. Moreover, the association of
androgenic obesity with hypertension, hipertriglyceridemia
and insulin resistance can also amplify the occurrence of
MetS and future CVD during the postmenopausal period.
Finally, the somatic and urogenital-sexual dysfunction could
also occurs more often in these women than in those present-
ing the gynoid pattern.
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